Risk factor
Resilient to price shocks
Profitability factor
Very strong margins and returns
About
Indraprastha Medical Corporation Limited (IMCL) is a prominent Indian healthcare provider, delivering a broad spectrum of hospital services across the nation. The company offers comprehensive medical and surgical solutions across an extensive range of specialties. Its offerings encompass areas like anesthesiology, pediatrics, elder care, genomic medicine, preventative health checks, and a variety of complex surgical interventions, including bariatric, metabolic, bone marrow, cardiac, endovascular, laparoscopic, robotic, spine, pediatric urology, pediatric surgery, transplant, and urology and andrology. Furthermore, IMCL provides specialized medical departments for cancer, cardiology, dermatology, dietetics and clinical nutrition, emergency care, endocrinology/diabetes, ENT, fetal medicine, gastroenterology and hepatology, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, internal medicine, laboratory services, neonatology, nephrology, neurosciences, nuclear medicine, ophthalmology, orthopedics, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology/radio diagnosis, respiratory sleep medicine and critical care, rheumatology, and transfusion medicine. In addition to its core hospital services, IMCL also operates dedicated cosmetic and dental clinics. Established in 1988, the corporation is headquartered in New Delhi, India.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, overvalued o
Target Price
The average target price of INDRAMEDCO.NS is 550 and suggests 52.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation